Citations

Showing 10 of 108104 citations.

Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nal-IRI) in the US.
Surinach, Andy , Corvino, Frank A., Torres, Aracelis Z. , Mamlouk, Khalid, Pulgar, Sonia, Barzi, Afsaneh , Miksad, Rebecca Anne , Wang, Siqi , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16229-e16229

10.1200/jco.2018.36.15_suppl.e16229 Get It

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.
Borazanci, Erkut , Jameson, Gayle , Downes, Michael , Truitt, Morgan , Patel, Hitendra , Lowy, Andrew M. , Roe, Denise J. , Ansaldo, Karen, Barrett, Michael T. , Korn, Ronald L. , Caldwell, Lana, Slethaug, Gavin, Hultsch, Rolf, Han, Haiyong , Engelthaler, David M. , Lenkiewics, Elizabeth, Hoff, Daniel D. Von , Borazanci, Erkut , Chung, Vincent , Evans, Ronald M. , Patel, Hitendra, Pearson, Talima

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4154-TPS4154

10.1200/jco.2018.36.15_suppl.tps4154 Get It

A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
Tan, Benjamin , Reiss, Kim Anna, Mody, Kabir , Khalil, Daniel, Nadolski, G. , Giardina, Joseph Daniel , Capanu, Marinela , Bradley, Mikaela , Boussayoud, Chayma, Valentino, Emily , Harding, James J. , Erinjeri, Joseph P. , Yarmohammadi, Hooman , Gian, Richard Kinh , Merghoub, Taha , Jarnagin, William R. , Soulen, Michael C , Brown, Karen T. , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4146-TPS4146

10.1200/jco.2018.36.15_suppl.tps4146 Get It

Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.
Picozzi, Vincent J. , Pishvaian, Michael J. , Mody, Kabir , Larson, Tim , Matrana, Marc , Saikali, Khalil G., Carney, Mairead, Porter, Seth, Yu, Peony, Kouchakji, Elias, Carrier, Ewa , Winter, Jordan Michael , Glaspy, John A. , Larson, Tim

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4016-4016

10.1200/jco.2018.36.15_suppl.4016 Get It

Curative intent of local excision alone for stage I anal canal squamous cell carcinoma (ACSCC).
Chakrabarti, Sakti , Huffman, Brandon M. , Hallemeier, Christopher L. , Grothey, Axel, Chakrabarti, Sakti , Jin, Zhaohui , Hallemeier, Christopher Leigh , Hubbard, Joleen M. , Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e15574-e15574

10.1200/jco.2018.36.15_suppl.e15574 Get It

Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.
Chakrabarti, Sakti , Sara, Jaskanwal Deep Singh , Lobo, Ronstan , Finnes, Heidi D. , Mitchelll, Jessica L, Hartgers, Mindy L., Okano, Akiko, Hálfdánarson, Þorvarður R. , Grothey, Axel, Halfdanarson, Thorvardur R , Chakrabarti, Sakti , Eiring, Rachel A. , Okano, Akiko

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e15513-e15513

10.1200/jco.2018.36.15_suppl.e15513 Get It

Body mass index and long-term outcomes in patients with colorectal cancer.
Cochuyt, Jordan J., Li, Zhuo , Merchea, Amit , Colibaseanu, Dorin , Shahjehan, Faisal , Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e15631-e15631

10.1200/jco.2018.36.15_suppl.e15631 Get It

Patient and tumor-related factors for sphincter-preserving surgery in patients with rectal cancer.
Mathis, Kellie L. , Merchea, Amit , Shahjehan, Faisal , Colibaseanu, Dorin , Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e15628-e15628

10.1200/jco.2018.36.15_suppl.e15628 Get It

Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
Горбунова, В. А. , Beck, Thaddeus, Hofheinz, Ralf‐Dieter , García‐Alfonso, Pilar , Nechaeva, Marina , Gracián, Antonio Cubillo, Mangel, László, Deming, Dustin A. , Ramanathan, Ramesh K., Torres, Alison Hewitt, Sullivan, Danielle, Komarnitsky, Philip, Élez, Elena , Berlin, Jordan D.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3543-3543

10.1200/jco.2018.36.15_suppl.3543 Get It

Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.
Gulhati, Pat , Yin, Jun , Pederson, Levi , Douillard, Jean‐Yves , Hecht, J. Randolph, Tournigand, Christophe , Tebbut, Niall, Chibaudel, Benoist , Gramont, Aimery de , Overman, Michael J. , Schmoll, Hans‐Joachim , Hoff, Paulo M. , Shi, Qian , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3525-3525

10.1200/jco.2018.36.15_suppl.3525 Get It